| アブストラクト | Background: In patients with allogenic hematopoietic stem cell transplantation (allo-HSCT), immune-checkpoint inhibitors (ICI) are used to treat malignancy recurrence. However, ICI are also associated with graft vs. host disease (GVHD). In this pharmacovigilance analysis, we aimed to characterize cases of GVHD associated with ICI, drawn from the World Health Organization pharmacovigilance database, VigiBase(R), and from literature. Methods: We performed VigiBase(R) query of cases of GVHD associated with ICI. These cases were combined with those of literature, not reported in VigiBase(R). The Bayesian estimate of disproportionality analysis, the information component, was considered significant if its 95% credibility interval lower bound was positive; denoting a significant association between GVHD and the suspected ICI. Time to onset between ICI and GVHD onset and subsequent mortality were assessed. Results: Disproportionality analysis yielded 93 cases of GVHD associated with ICI (61.8% men, median age 38 [interquartile range = 27; 50] years). Cases were mostly associated with nivolumab (53/93, 57.0%), pembrolizumab (23/93, 24.7%) and ipilimumab (12/93, 12.9%) monotherapies. GVHD events occurred after 1 [1; 5.5] injection of ICI, with a time to onset of 35 [IQR = 14; 176] days. Immediate subsequent mortality after GVHD was 24/93, 25.8%. There was no significant difference in mortality depending on the molecule (p = 0.41) or the combination regimen (combined vs. monotherapy, p = 0.60). Previous history of GVHD was present in 11/18, 61.1% in cases reported in literature. Conclusion: In this worldwide pharmacovigilance study, disproportionality yielded significant association between GVHD and ICI, with subsequent mortality of 25.8%. Previous history of GVHD was reported in more than half of cases. Clinicaltrials.gov identifier: NCT03492242. |
|---|
| ジャーナル名 | Frontiers in pharmacology |
|---|
| Pubmed追加日 | 2021/2/23 |
|---|
| 投稿者 | Nguyen, Lee S; Raia, Lisa; Lebrun-Vignes, Benedicte; Salem, Joe-Elie |
|---|
| 組織名 | CMC Ambroise Pare, Research and Innovation-RICAP, Neuilly-sur-Seine, France.;Sorbonne Universite, Clinical Investigations Center Paris-Est, AP.HP.6;Pitie-Salpetriere University Hospital, INSERM, Paris, France.;Intensive Care Medicine Department, AP.HP.Centre Cochin University Hospital,;Paris, France.;Creteil Paris-Est University, EpiderMe, Creteil, France.;Department of Medicine, Cardio-Oncology Program, Vanderbilt University Medical;Center, Nashville, TN, United States. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/33613286/ |
|---|
